Schedule 13G ownership disclosure
Monte Rosa Therapeutics Inc
COMMON STOCK · CUSIP: 61225M102
Event date: 2025-09-30
- Filing-level shares
- 4,637,060
- Percent of class
- 7.5%
- T. Rowe Price Associates, Inc.
Shares: 4,637,060 · Class: 7.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000838
- Form type
- SCHEDULE 13G/A
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership